Arcadia Biosciences Net Income
| RKDA Stock | USD 1.68 0.06 3.45% |
As of the 16th of February 2026, Arcadia Biosciences shows the risk adjusted performance of (0.14), and Coefficient Of Variation of (545.39). In respect to fundamental indicators, the technical analysis model gives you tools to check existing technical drivers of Arcadia Biosciences, as well as the relationship between them.
Arcadia Biosciences Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 0.0576 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Loss | -5 M | -5.2 M | |
| Net Loss | -5 M | -5.2 M | |
| Net Loss | -16.9 M | -17.7 M | |
| Net Loss | (4.65) | (4.88) | |
| Net Income Per E B T | 1.47 | 0.98 |
Arcadia | Net Income | Build AI portfolio with Arcadia Stock |
Analyzing Arcadia Biosciences's Net Income over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Income has evolved provides context for assessing Arcadia Biosciences's current valuation and future prospects.
Latest Arcadia Biosciences' Net Income Growth Pattern
Below is the plot of the Net Income of Arcadia Biosciences over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Arcadia Biosciences financial statement analysis. It represents the amount of money remaining after all of Arcadia Biosciences operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Arcadia Biosciences' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Arcadia Biosciences' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (4.32 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Arcadia Net Income Regression Statistics
| Arithmetic Mean | (13,912,829) | |
| Coefficient Of Variation | (40.19) | |
| Mean Deviation | 3,899,456 | |
| Median | (13,480,000) | |
| Standard Deviation | 5,591,556 | |
| Sample Variance | 31.3T | |
| Range | 24.1M | |
| R-Value | 0.28 | |
| Mean Square Error | 30.7T | |
| R-Squared | 0.08 | |
| Significance | 0.27 | |
| Slope | 312,620 | |
| Total Sum of Squares | 500.2T |
Arcadia Net Income History
Other Fundumenentals of Arcadia Biosciences
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Arcadia Biosciences Net Income component correlations
Arcadia Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Arcadia Biosciences is extremely important. It helps to project a fair market value of Arcadia Stock properly, considering its historical fundamentals such as Net Income. Since Arcadia Biosciences' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Arcadia Biosciences' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Arcadia Biosciences' interrelated accounts and indicators.
Click cells to compare fundamentals
Is Agricultural Products & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Arcadia Biosciences. Anticipated expansion of Arcadia directly elevates investor willingness to pay premium valuations. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Arcadia Biosciences assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth 0.285 | Earnings Share (3.69) | Revenue Per Share | Quarterly Revenue Growth (0.15) | Return On Assets |
Understanding Arcadia Biosciences requires distinguishing between market price and book value, where the latter reflects Arcadia's accounting equity. The concept of intrinsic value - what Arcadia Biosciences' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Arcadia Biosciences' price substantially above or below its fundamental value.
It's important to distinguish between Arcadia Biosciences' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Arcadia Biosciences should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Arcadia Biosciences' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Arcadia Biosciences 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Arcadia Biosciences' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Arcadia Biosciences.
| 11/18/2025 |
| 02/16/2026 |
If you would invest 0.00 in Arcadia Biosciences on November 18, 2025 and sell it all today you would earn a total of 0.00 from holding Arcadia Biosciences or generate 0.0% return on investment in Arcadia Biosciences over 90 days. Arcadia Biosciences is related to or competes with Capstone Holding, N2OFF, CN Energy, Gulf Resources, IT Tech, Inno Holdings, and ReTo Eco. Arcadia Biosciences, Inc. produces and markets plant-based health and wellness products in the United States More
Arcadia Biosciences Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Arcadia Biosciences' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Arcadia Biosciences upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.20) | |||
| Maximum Drawdown | 25.74 | |||
| Value At Risk | (11.64) | |||
| Potential Upside | 8.59 |
Arcadia Biosciences Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Arcadia Biosciences' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Arcadia Biosciences' standard deviation. In reality, there are many statistical measures that can use Arcadia Biosciences historical prices to predict the future Arcadia Biosciences' volatility.| Risk Adjusted Performance | (0.14) | |||
| Total Risk Alpha | (1.42) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Arcadia Biosciences' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Arcadia Biosciences February 16, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.14) | |||
| Mean Deviation | 3.58 | |||
| Coefficient Of Variation | (545.39) | |||
| Standard Deviation | 5.46 | |||
| Variance | 29.83 | |||
| Information Ratio | (0.20) | |||
| Total Risk Alpha | (1.42) | |||
| Maximum Drawdown | 25.74 | |||
| Value At Risk | (11.64) | |||
| Potential Upside | 8.59 | |||
| Skewness | (0.27) | |||
| Kurtosis | 2.4 |
Arcadia Biosciences Backtested Returns
Arcadia Biosciences secures Sharpe Ratio (or Efficiency) of -0.2, which signifies that the company had a -0.2 % return per unit of standard deviation over the last 3 months. Arcadia Biosciences exposes twenty different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Arcadia Biosciences' coefficient of variation of (545.39), and Risk Adjusted Performance of (0.14) to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of 0.0, which signifies not very significant fluctuations relative to the market. the returns on MARKET and Arcadia Biosciences are completely uncorrelated. At this point, Arcadia Biosciences has a negative expected return of -1.13%. Please make sure to confirm Arcadia Biosciences' information ratio, daily balance of power, period momentum indicator, as well as the relationship between the value at risk and day typical price , to decide if Arcadia Biosciences performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.67 |
Good predictability
Arcadia Biosciences has good predictability. Overlapping area represents the amount of predictability between Arcadia Biosciences time series from 18th of November 2025 to 2nd of January 2026 and 2nd of January 2026 to 16th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Arcadia Biosciences price movement. The serial correlation of 0.67 indicates that around 67.0% of current Arcadia Biosciences price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.67 | |
| Spearman Rank Test | 0.39 | |
| Residual Average | 0.0 | |
| Price Variance | 0.08 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Arcadia Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Arcadia Biosciences reported net income of (4.32 Million). This is 64.13% lower than that of the Food Products sector and 101.86% lower than that of the Consumer Staples industry. The net income for all United States stocks is 100.76% higher than that of the company.
Arcadia Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Arcadia Biosciences' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Arcadia Biosciences could also be used in its relative valuation, which is a method of valuing Arcadia Biosciences by comparing valuation metrics of similar companies.Arcadia Biosciences is currently under evaluation in net income category among its peers.
Arcadia Biosciences Institutional Holders
Institutional Holdings refers to the ownership stake in Arcadia Biosciences that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Arcadia Biosciences' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Arcadia Biosciences' value.| Shares | Bank Of America Corp | 2025-06-30 | 13.0 | Genworth Financial Wealth Mgmt Inc | 2025-06-30 | 5.0 | Harbour Investments, Inc. | 2025-06-30 | 1.0 | Larson Financial Group, Llc | 2025-06-30 | 0.0 | Mariner Wealth Advisors Llc | 2025-06-30 | 14.5 K | Vanguard Group Inc | 2025-06-30 | 14 K | Geode Capital Management, Llc | 2025-06-30 | 12.8 K | State Street Corp | 2025-06-30 | 12.1 K | Ubs Group Ag | 2025-06-30 | 2.5 K | Tower Research Capital Llc | 2025-06-30 | 1.9 K | Morgan Stanley - Brokerage Accounts | 2025-06-30 | 787 |
Arcadia Fundamentals
| Return On Equity | -0.65 | ||||
| Return On Asset | -0.31 | ||||
| Profit Margin | (0.98) % | ||||
| Operating Margin | (0.88) % | ||||
| Current Valuation | (1.53 M) | ||||
| Shares Outstanding | 1.73 M | ||||
| Shares Owned By Insiders | 0.32 % | ||||
| Shares Owned By Institutions | 1.15 % | ||||
| Number Of Shares Shorted | 10.9 K | ||||
| Price To Earning | 4.84 X | ||||
| Price To Book | 0.53 X | ||||
| Price To Sales | 0.71 X | ||||
| Revenue | 5.04 M | ||||
| Gross Profit | 2.09 M | ||||
| EBITDA | (7.5 M) | ||||
| Net Income | (4.32 M) | ||||
| Cash And Equivalents | 21.23 M | ||||
| Cash Per Share | 0.96 X | ||||
| Total Debt | 155 K | ||||
| Debt To Equity | 0.09 % | ||||
| Current Ratio | 6.34 X | ||||
| Book Value Per Share | 3.98 X | ||||
| Cash Flow From Operations | (9.63 M) | ||||
| Short Ratio | 0.33 X | ||||
| Earnings Per Share | (3.69) X | ||||
| Price To Earnings To Growth | (0.08) X | ||||
| Target Price | 12.0 | ||||
| Beta | 0.57 | ||||
| Market Capitalization | 3.66 M | ||||
| Total Asset | 13.52 M | ||||
| Retained Earnings | (278.88 M) | ||||
| Working Capital | 6.68 M | ||||
| Current Asset | 52.02 M | ||||
| Current Liabilities | 3.45 M | ||||
| Net Asset | 13.52 M |
About Arcadia Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Arcadia Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Arcadia Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Arcadia Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Arcadia Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Arcadia Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Arcadia Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Arcadia Biosciences Stock:Check out For information on how to trade Arcadia Stock refer to our How to Trade Arcadia Stock guide.You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
Is Agricultural Products & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Arcadia Biosciences. Anticipated expansion of Arcadia directly elevates investor willingness to pay premium valuations. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Arcadia Biosciences assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth 0.285 | Earnings Share (3.69) | Revenue Per Share | Quarterly Revenue Growth (0.15) | Return On Assets |
Understanding Arcadia Biosciences requires distinguishing between market price and book value, where the latter reflects Arcadia's accounting equity. The concept of intrinsic value - what Arcadia Biosciences' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Arcadia Biosciences' price substantially above or below its fundamental value.
It's important to distinguish between Arcadia Biosciences' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Arcadia Biosciences should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Arcadia Biosciences' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.